Faron Pharmaceuticals Oy

As a condition with fewer treatment options, myelodysplastic syndrome (MDS) patients require long-term and treatment resistant solutions. Aiming to address this unmet need, Faron Pharmaceuticals conti

Following a mutual agreement, Gilead Sciences, Inc. has waived its option to acquire Pionyr Immunotherapeutics Inc. for a pre-set price, enabling Pionyr to shop around for new opportunities as mac

The positive Phase III results and subsequent US approval of lecanemab for Alzheimer’s disease was reflected by a spike in enthusiasm for the central nervous system (CNS) space among the 90 or so resp

After a couple of years in the doldrums, Faron Pharmaceuticals Oy 's star is rising again on the prospects of its next-generation immunotherapy bexmarilimab becoming a blockbuster. The Finland-headqu